eClinical Technology and Industry News

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role

Appointments reflect ARTBIO’s commitment to utilizing world-class experience and insights needed to advance alpha radioligand programs

Company Co-founder Roy Larsen, Ph.D. will transition from Board of Directors to a new Technical Advisory Board within ARTBIO

Excerpt from the Press Release:

CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ — ARTBIO, Inc. (“ARTBIO”), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), today announced four appointments to its Board of Directors:

  • Maha Katabi, Ph.D., CFA is a General Partner at Sofinnova Investments. With more than two decades of experience in managing public and private biotech companies, Dr. Katabi will advise ARTBIO in their work to maximize investments for operations and growth strategies. Dr. Katabi received a Ph.D. in Pharmacology at McGill University and is a CFA Charterholder. Dr. Katabi was part of the early investment syndicate at RayzeBio, which was acquired by BMS in 2024. She currently serves on several public and private company boards.
  • Robert Mittendorff, M.D., MBA is a General Partner and Head of Healthcare at B Capital Group, a global investment firm. His 20 years of experience as both a physician and public company executive will support ARTBIO’s program expansion strategy. Dr. Mittendorff received his M.D. from Harvard University and MIT in the HST Program, and his MBA from Harvard Business School. Prior to B Capital Group, Dr. Mittendorff worked at Hansen Medical Inc., Merck, Boston Consulting Group, and at Kaiser Permanente.
  • Julie O’Neill, MBA (Independent Director) is an experienced healthcare leader, having held senior manufacturing and operations roles at Alexion Pharmaceuticals and Gilead Sciences. She also chairs the board of Ireland’s National Institute for Bioprocessing Research and Training. Mrs. O’Neill holds a Bachelor of Science in Pharmacy from Trinity College Dublin, an MBA from University College Dublin, and is a Chartered Director of The Institute of Directors in Ireland. Mrs. O’Neill serves on the boards of ICON plc, DBV Technologies, and Advancion Sciences (formerly Angus Chemical Company)

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Categories

Archives